MedPath

A verification study of enhancement of the immune system

Not Applicable
Conditions
Healthy Japanese subjects
Registration Number
JPRN-UMIN000036610
Lead Sponsor
ORTHOMEDICO Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
32
Inclusion Criteria

Not provided

Exclusion Criteria

1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Function Claims", or other functional food/beverage in daily 5. Subjects who are currently taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are pregnant, lactation, or planning to become pregnant 8. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to enroll in anther clinical trial during trial period 9. Subjects who are ineligibility to participate in the study based on the evaluation of the principal physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Scoring of immunological vigor * Assess the measured value at screening (before consumption) and at 4 weeks after consumption or calculate the amount of change.
Secondary Outcome Measures
NameTimeMethod
1. T lymphocyte age 2. Number of T cells 3. CD4+T cells/CD8+ T cells ratio 4. Number of naive T cells 5. Naive T cells/memory T cells ratio 6. Number of B cells 7. Number of NK cells 8. Number of CD8+CD28+T cells 9. Subjective symptoms (The Likert scale method) *1-8 Assess the measured value at screening (before consumption) and at 4 weeks after consumption or calculate the amount of change. *9 Assess the measured value at screening (before consumption) and at 4 weeks after consumption.
© Copyright 2025. All Rights Reserved by MedPath